New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
06:17 EDTARDXArdelyx 4.286M share IPO priced at $14.00
The deal was increased to 4.286M shares from 3.6M shares and priced between the $13.00-$15.00 range. Citigroup and Leerink acted as joint book running managers for the offering.
News For ARDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
17:12 EDTARDXArdelyx tenapanor reduces phosphorus absorption
Ardelyx announced publication of data in the Journal of the American Society of Nephrology, or JASN, showing that in a preclinical in vivo model of chronic kidney disease, or CKD, tenapanor reduced phosphorus absorption and protected against vascular calcification. Tenapanor, a minimally-systemic inhibitor of the intestinal sodium transporter NHE3, has demonstrated the ability to reduce the absorption of dietary sodium and phosphorus in human and animal studies. According to the research findings reported in JASN, tenapanor decreased phosphorus absorption in rats, both in a setting of normal renal function and in a model of CKD. In the normal renal function group, tenapanor administration resulted in significantly decreased urinary phosphate excretion. In a model of CKD, administration of tenapanor consistently lowered urinary phosphorus excretion over the course of 28 days compared with untreated controls. Additionally, in a CKD model of vascular calcification, tenapanor reduced serum phosphorus and serum creatinine as well as soft tissue calcification, as shown by significantly reduced phosphorous and calcium content of the aortic arch and stomach compared with vehicle treatment. Tenapanor-treated animals also demonstrated significant attenuation of renal and cardiac hypertrophy, signs of a compromised kidney and heart. Tenapanor in this model also reduced the expression of FGF-23, an important hormone suspected to aggravate vascular calcification and heart hypertrophy in CKD.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use